Please provide your email address to receive an email when new articles are posted on . Human growth hormone therapy was associated with increased risk for proximal tibial physeal avulsion fractures.

Pfizer Inc. PFE said Wednesday the U.S. Food and Drug Administration has approved its Ngenla once-weekly, human growth hormone treatment for children aged three and older who have growth failure due ...

Pediatric growth hormone deficiency (PGHD) is a genetic condition that affects your child’s physical development. Hormone replacement therapy can help promote growth, and a new injection now makes it ...

Imagine a component in your body that assists you in transforming from a child into a mature person, helps your body heal itself when you get injured, and also keeps you healthy as you get older. One ...

Recent research findings put a spotlight on the link between human growth hormone (HGH) and Alzheimer’s disease. Could taking HGH increase your risk of Alzheimer’s? Ultimately, scientists say they ...

In a bid to protect sales for its human growth hormone drug Genotropin, Pfizer licensed rights to a longer-lasting human growth hormone therapy, hGH-CTP, in December. This longer-lasting drug has just ...

The National Institute for Clinical Excellence, (NICE), recommended in its guidance to the National Health Service that recombinant human growth hormone treatment - somatropin (rbe) - is an effective ...

(CNN) — Early-onset dementia symptoms in five adults may be connected to a now-discontinued human growth hormone medical treatment that they received decades ago as children, a new study suggests.

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a ...